File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: MicroRNA expression, survival, and response to interferon in liver cancer

TitleMicroRNA expression, survival, and response to interferon in liver cancer
Authors
Issue Date2009
PublisherMassachusetts Medical Society. The Journal's web site is located at http://content.nejm.org/
Citation
New England Journal Of Medicine, 2009, v. 361 n. 15, p. 1437-1447 How to Cite?
AbstractBACKGROUND: Hepatocellular carcinoma is a common and aggressive cancer that occurs mainly in men. We examined microRNA expression patterns, survival, and response to interferon alfa in both men and women with the disease. METHODS: We analyzed three independent cohorts that included a total of 455 patients with hepatocellular carcinoma who had undergone radical tumor resection between 1999 and 2003. MicroRNA-expression profiling was performed in a cohort of 241 patients with hepatocellular carcinoma to identify tumor-related microRNAs and determine their association with survival in men and women. In addition, to validate our findings, we used quantitative reverse-transcriptase-polymerase- chain-reaction assays to measure microRNAs and assess their association with survival and response to therapy with interferon alfa in 214 patients from two independent, prospective, randomized, controlled trials of adjuvant interferon therapy. RESULTS: In patients with hepatocellular carcinoma, the expression of miR-26a and miR-26b in nontumor liver tissue was higher in women than in men. Tumors had reduced levels of miR-26 expression, as compared with paired noncancerous tissues, which indicated that the level of miR-26 expression was also associated with hepatocellular carcinoma. Moreover, tumors with reduced miR-26 expression had a distinct transcriptomic pattern, and analyses of gene networks revealed that activation of signaling pathways between nuclear factor κB and interleukin-6 might play a role in tumor development. Patients whose tumors had low miR-26 expression had shorter overall survival but a better response to interferon therapy than did patients whose tumors had high expression of the microRNA. CONCLUSIONS: The expression patterns of microRNAs in liver tissue differ between men and women with hepatocellular carcinoma. The miR-26 expression status of such patients is associated with survival and response to adjuvant therapy with interferon alfa. Copyright © 2009 Massachusetts Medical Society. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/88347
ISSN
2014 Impact Factor: 55.873
2014 SCImago Journal Rankings: 12.155
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
Intramural Research Program of the Center for Cancer Research of the National Cancer InstituteZ01-BC 010313
Z01-BC 010876
Funding Information:

Supported in part by grants (Z01-BC 010313 and Z01-BC 010876) from the Intramural Research Program of the Center for Cancer Research of the National Cancer Institute.

References

 

DC FieldValueLanguage
dc.contributor.authorJi, Jen_HK
dc.contributor.authorShi, Jen_HK
dc.contributor.authorBudhu, Aen_HK
dc.contributor.authorYu, Zen_HK
dc.contributor.authorForgues, Men_HK
dc.contributor.authorRoessler, Sen_HK
dc.contributor.authorAmbs, Sen_HK
dc.contributor.authorChen, Yen_HK
dc.contributor.authorMeltzer, PSen_HK
dc.contributor.authorCroce, CMen_HK
dc.contributor.authorQin, LXen_HK
dc.contributor.authorMan, Ken_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorLee, Jen_HK
dc.contributor.authorNg, IOLen_HK
dc.contributor.authorFan, Jen_HK
dc.contributor.authorTang, ZYen_HK
dc.contributor.authorSun, HCen_HK
dc.contributor.authorWang, XWen_HK
dc.date.accessioned2010-09-06T09:42:11Z-
dc.date.available2010-09-06T09:42:11Z-
dc.date.issued2009en_HK
dc.identifier.citationNew England Journal Of Medicine, 2009, v. 361 n. 15, p. 1437-1447en_HK
dc.identifier.issn0028-4793en_HK
dc.identifier.urihttp://hdl.handle.net/10722/88347-
dc.description.abstractBACKGROUND: Hepatocellular carcinoma is a common and aggressive cancer that occurs mainly in men. We examined microRNA expression patterns, survival, and response to interferon alfa in both men and women with the disease. METHODS: We analyzed three independent cohorts that included a total of 455 patients with hepatocellular carcinoma who had undergone radical tumor resection between 1999 and 2003. MicroRNA-expression profiling was performed in a cohort of 241 patients with hepatocellular carcinoma to identify tumor-related microRNAs and determine their association with survival in men and women. In addition, to validate our findings, we used quantitative reverse-transcriptase-polymerase- chain-reaction assays to measure microRNAs and assess their association with survival and response to therapy with interferon alfa in 214 patients from two independent, prospective, randomized, controlled trials of adjuvant interferon therapy. RESULTS: In patients with hepatocellular carcinoma, the expression of miR-26a and miR-26b in nontumor liver tissue was higher in women than in men. Tumors had reduced levels of miR-26 expression, as compared with paired noncancerous tissues, which indicated that the level of miR-26 expression was also associated with hepatocellular carcinoma. Moreover, tumors with reduced miR-26 expression had a distinct transcriptomic pattern, and analyses of gene networks revealed that activation of signaling pathways between nuclear factor κB and interleukin-6 might play a role in tumor development. Patients whose tumors had low miR-26 expression had shorter overall survival but a better response to interferon therapy than did patients whose tumors had high expression of the microRNA. CONCLUSIONS: The expression patterns of microRNAs in liver tissue differ between men and women with hepatocellular carcinoma. The miR-26 expression status of such patients is associated with survival and response to adjuvant therapy with interferon alfa. Copyright © 2009 Massachusetts Medical Society. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherMassachusetts Medical Society. The Journal's web site is located at http://content.nejm.org/en_HK
dc.relation.ispartofNew England Journal of Medicineen_HK
dc.rightsNew England Journal of Medicine. Copyright © Massachusetts Medical Society.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAntiviral Agents - therapeutic use-
dc.subject.meshCarcinoma, Hepatocellular - drug therapy - genetics - mortality-
dc.subject.meshGene Expression-
dc.subject.meshInterferon-alpha - therapeutic use-
dc.subject.meshLiver Neoplasms - drug therapy - genetics - mortality-
dc.titleMicroRNA expression, survival, and response to interferon in liver canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0028-4793&volume=361&issue=15&spage=1437&epage=1447&date=2009&atitle=MicroRNA+expression,+survival,+and+response+to+interferon+in+liver+canceren_HK
dc.identifier.emailMan, K: kwanman@hkucc.hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailNg, IOL: iolng@hkucc.hku.hken_HK
dc.identifier.authorityMan, K=rp00417en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityNg, IOL=rp00335en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1056/NEJMoa0901282en_HK
dc.identifier.pmid19812400en_HK
dc.identifier.pmcidPMC2786938-
dc.identifier.scopuseid_2-s2.0-70349871321en_HK
dc.identifier.hkuros168549en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70349871321&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume361en_HK
dc.identifier.issue15en_HK
dc.identifier.spage1437en_HK
dc.identifier.epage1447en_HK
dc.identifier.isiWOS:000270540000005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.f10001382977-
dc.identifier.scopusauthoridJi, J=7201362455en_HK
dc.identifier.scopusauthoridShi, J=7404495464en_HK
dc.identifier.scopusauthoridBudhu, A=6507301846en_HK
dc.identifier.scopusauthoridYu, Z=8770380900en_HK
dc.identifier.scopusauthoridForgues, M=6602363144en_HK
dc.identifier.scopusauthoridRoessler, S=12243081900en_HK
dc.identifier.scopusauthoridAmbs, S=6602816824en_HK
dc.identifier.scopusauthoridChen, Y=7601431107en_HK
dc.identifier.scopusauthoridMeltzer, PS=7102464641en_HK
dc.identifier.scopusauthoridCroce, CM=34569630600en_HK
dc.identifier.scopusauthoridQin, LX=16747601200en_HK
dc.identifier.scopusauthoridMan, K=7101754072en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridLee, J=36065603500en_HK
dc.identifier.scopusauthoridNg, IOL=7102753722en_HK
dc.identifier.scopusauthoridFan, J=7402794379en_HK
dc.identifier.scopusauthoridTang, ZY=7403306295en_HK
dc.identifier.scopusauthoridSun, HC=35723133900en_HK
dc.identifier.scopusauthoridWang, XW=8712734700en_HK
dc.identifier.citeulike5955877-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats